McAdam LLC Raises Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

McAdam LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 16.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 25,372 shares of the biopharmaceutical company's stock after purchasing an additional 3,627 shares during the quarter. McAdam LLC's holdings in Gilead Sciences were worth $2,344,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of GILD. nVerses Capital LLC acquired a new position in Gilead Sciences in the 3rd quarter valued at about $25,000. Valued Wealth Advisors LLC grew its holdings in Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 161 shares during the period. Decker Retirement Planning Inc. purchased a new stake in Gilead Sciences in the 4th quarter valued at about $29,000. Crews Bank & Trust purchased a new stake in Gilead Sciences in the 4th quarter valued at about $31,000. Finally, Quarry LP purchased a new stake in Gilead Sciences in the 2nd quarter valued at about $43,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the transaction, the insider now owns 80,801 shares of the company's stock, valued at approximately $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 572,824 shares of company stock valued at $53,611,715. Corporate insiders own 0.29% of the company's stock.

Wall Street Analyst Weigh In

GILD has been the subject of a number of research reports. Citigroup initiated coverage on Gilead Sciences in a report on Thursday, November 14th. They set a "buy" rating and a $125.00 target price for the company. The Goldman Sachs Group boosted their target price on Gilead Sciences from $74.00 to $84.00 and gave the stock a "neutral" rating in a report on Thursday, November 7th. UBS Group upped their price target on Gilead Sciences from $70.00 to $96.00 and gave the stock a "neutral" rating in a report on Thursday, November 21st. Bank of America restated a "buy" rating and issued a $109.00 price target on shares of Gilead Sciences in a report on Tuesday, December 10th. Finally, Royal Bank of Canada restated a "sector perform" rating and issued a $84.00 price target on shares of Gilead Sciences in a report on Monday. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $98.39.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded up $1.61 during midday trading on Wednesday, reaching $99.60. The company had a trading volume of 5,151,513 shares, compared to its average volume of 6,888,638. The business's 50-day simple moving average is $92.71 and its 200 day simple moving average is $86.32. The stock has a market cap of $124.13 billion, a P/E ratio of 1,107.07, a P/E/G ratio of 1.37 and a beta of 0.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $100.51. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion during the quarter, compared to analysts' expectations of $7.01 billion. During the same quarter in the previous year, the company earned $2.29 earnings per share. The firm's revenue for the quarter was up 7.0% on a year-over-year basis. On average, analysts forecast that Gilead Sciences, Inc. will post 4.34 earnings per share for the current fiscal year.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.